TNSN00169A1 - Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant - Google Patents
Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN00169A1 TNSN00169A1 TNTNSN00169A TNSN00169A TNSN00169A1 TN SN00169 A1 TNSN00169 A1 TN SN00169A1 TN TNSN00169 A TNTNSN00169 A TN TNSN00169A TN SN00169 A TNSN00169 A TN SN00169A TN SN00169 A1 TNSN00169 A1 TN SN00169A1
- Authority
- TN
- Tunisia
- Prior art keywords
- triones
- pyrimidine
- pharmaceutical compositions
- compositions containing
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
LA PRESENTE INVENTION CONCERNE DES INHIBITEURS DE METALLOPROTEINASES, CONSISTANT EN PYRIMIDINE-2,4,6- TRIONES DE FORMULE I :DANS LAQUELLE X,Y,AR1,Z,R1,R2 ET R3 REPRESENTENT DIVERS RADICAUX . ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION POUR LA FABRICATION DE MEDICAMENTS. APPLICATION : METHODES POUR LE TRAITEMENT DE DIVERSES MALADIES, NOTAMMENT DE L'INFLAMMATION ET DU CANCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14854799P | 1999-08-12 | 1999-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN00169A1 true TNSN00169A1 (fr) | 2005-11-10 |
Family
ID=22526231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN00169A TNSN00169A1 (fr) | 1999-08-12 | 2000-08-11 | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant |
Country Status (41)
Country | Link |
---|---|
US (1) | US6579982B1 (fr) |
EP (1) | EP1202974B1 (fr) |
JP (1) | JP2003507371A (fr) |
KR (2) | KR20040073608A (fr) |
CN (1) | CN1156454C (fr) |
AR (1) | AR025091A1 (fr) |
AT (1) | ATE309224T1 (fr) |
AU (1) | AU773751B2 (fr) |
BG (1) | BG106406A (fr) |
BR (1) | BR0013081A (fr) |
CA (1) | CA2381551A1 (fr) |
CO (1) | CO5180629A1 (fr) |
CR (1) | CR6565A (fr) |
CZ (1) | CZ2002355A3 (fr) |
DE (1) | DE60023903D1 (fr) |
EA (1) | EA004680B1 (fr) |
EC (1) | ECSP003610A (fr) |
EE (1) | EE200200069A (fr) |
GE (1) | GEP20053424B (fr) |
GT (1) | GT200000137A (fr) |
HK (1) | HK1045995B (fr) |
HN (1) | HN2000000137A (fr) |
HR (1) | HRP20020129A2 (fr) |
HU (1) | HUP0202501A3 (fr) |
IL (1) | IL148035A0 (fr) |
IS (1) | IS6248A (fr) |
MA (1) | MA26812A1 (fr) |
MX (1) | MXPA02001561A (fr) |
NO (1) | NO20020662L (fr) |
NZ (1) | NZ516562A (fr) |
OA (1) | OA12000A (fr) |
PA (1) | PA8498701A1 (fr) |
PE (1) | PE20010491A1 (fr) |
PL (1) | PL353871A1 (fr) |
SK (1) | SK1652002A3 (fr) |
TN (1) | TNSN00169A1 (fr) |
TR (1) | TR200200381T2 (fr) |
UY (1) | UY26285A1 (fr) |
WO (1) | WO2001012611A1 (fr) |
YU (1) | YU6602A (fr) |
ZA (1) | ZA200201070B (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
EA200300409A1 (ru) * | 2000-10-26 | 2003-08-28 | Пфайзер Продактс Инк. | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы |
CN1501937A (zh) * | 2000-10-26 | 2004-06-02 | �Ʒ� | 螺-嘧啶-2,4,6-三酮金属蛋白酶抑制剂 |
MXPA03005870A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibirores de benzotiadiazina de metaloproteinasas de la matriz. |
DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
DE60236851D1 (en) | 2001-02-14 | 2010-08-12 | Warner Lambert Co | Pyrimidinmatrixmetalloproteinaseinhibitoren |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
CA2462442A1 (fr) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
US6936620B2 (en) | 2001-12-20 | 2005-08-30 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
JP2005529889A (ja) * | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | ピリミジン−2,4,6−トリオンメタロ−プロテイナーゼ阻害剤 |
DE60302150D1 (en) * | 2002-04-26 | 2005-12-08 | Pfizer Prod Inc | N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren |
JP2005527598A (ja) * | 2002-04-26 | 2005-09-15 | ファイザー・プロダクツ・インク | トリアリール−オキシ−アリール−スピロ−ピリミジン−2,4,6−トリオンメタロプロテイナーゼ阻害剤 |
NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
AU2003253176A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
WO2004014908A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinases heterobicycliques |
CA2497656A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle |
WO2004084903A1 (fr) * | 2003-03-27 | 2004-10-07 | F. Hoffmann-La Roche Ag | Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire |
WO2004084902A1 (fr) * | 2003-03-28 | 2004-10-07 | F. Hoffmann-La Roche Ag | Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques |
ES2537514T3 (es) | 2003-04-04 | 2015-06-09 | Incyte Corporation | Composiciones, métodos y kits relacionados con la escisión de HER-2 |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
WO2012014109A1 (fr) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Sulfamides hétérocycliques servant d'inhibiteurs de synthétase d'arn de transfert, destinés à être utilisés en tant qu'agents antibactériens |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
US20150366275A1 (en) * | 2014-06-19 | 2015-12-24 | Gyula Cserfoi | Wearable Signaling Device |
GB201705255D0 (en) | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2263932A1 (fr) * | 1996-08-28 | 1998-03-05 | Yetunde Olabisi Taiwo | Inhibiteurs 1,4-heterocycliques de metalloproteases |
DE69831233T2 (de) * | 1997-06-21 | 2006-06-01 | Roche Diagnostics Gmbh | Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung |
-
2000
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/fr active IP Right Grant
- 2000-08-03 CA CA002381551A patent/CA2381551A1/fr not_active Abandoned
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Application Discontinuation
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko active IP Right Grant
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 EP EP00946235A patent/EP1202974B1/fr not_active Expired - Lifetime
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
-
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown
- 2002-02-12 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2002-10-17 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN00169A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN01149A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant. | |
TNSN01150A1 (fr) | Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant. | |
TNSN99073A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99055A1 (fr) | Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98022A1 (fr) | DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. | |
TNSN00036A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN01048A1 (fr) | Acides malonamiques et leurs derives, et compositions les contenant | |
TNSN99252A1 (fr) | Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant. | |
TNSN01114A1 (fr) | Derives d'imidazole nouveaux et compositions les contenant | |
TNSN00191A1 (fr) | Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie | |
TNSN01047A1 (fr) | Procede pour la preparation de derives de piperazine nouveaux | |
TNSN00028A1 (fr) | Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN98019A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN98045A1 (fr) | Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
TNSN99126A1 (fr) | Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN01020A1 (fr) | Derives heterocycliques benzocondenses de nicotinamide, et compositions les contenant | |
TNSN02009A1 (fr) | Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant. | |
TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97122A1 (fr) | Inhibiteurs des metalloproteinases de matrice a base de phosphinates |